- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
26 Cards in this Set
- Front
- Back
|
Synthroid
|
Indication: Hypothyroidism
Replacement Therapy: Levothyroxine T4 - Synthroid Liothyronine T3 Liotrix mixture of -T4 and T3 in a 4:1 -ratio No drug interactions No adverse effects |
|
Radioactive Iodine
|
Indication: Hyperthyroidism
Drug is concentrated in thyroid, where the β particles destroy the gland Adverse: Hypothyroidism |
|
Propylthiouracil
|
Indication: Hyperthyroidism
Inhibits thyroid peroxidase, an enzyme responsible for the synthesis of thyroid hormones Surgery Adverse Effect: Hypothyroidism |
|
Methyltestosterone
|
Class: Androgen
Indications: delayed puberty in males breast cancer therapy after testicular cancer Controversial indications: enhancement of athletic performance female hypo-gonadism male contraception catabolic and wasting states (cancer, AIDS) blood dyscrasias Adverse: Hair growth, acne, baldness, virilization, gynecomastia Dyslipidemia Prostate hypertrophy, cancer Jaundice Osteoporosis Behavioral effects: “Roid rage” |
|
Finasteride (Proscar, Propecia)
|
Class: Anti-androgen
5 α-reductase: enzyme testosterone to dihydroxytestosterone Mediator of the actions of the hormone Testosterone can be aromatized to estrogen, DHT cannot Competitive inhibitor of 5 α-reductase: - Benign prostatic hypertrophy (Proscar), -Alopecia (Propecia) |
|
Estrogen/Progesterone
|
Indications:
Pre-menopausal women -Birth control -Adolescents when puberty is absent Post-menopausal women -Prevention of osteoporosis related fractures -Vasomotor symptoms -Controversial in women over 60: CVD, breast cancer, stroke, DVT |
|
Oral Contraceptives
|
MOA: Inhibits the hypothalamus and pituitary from releasing LH and FSH which leads to ovulation
Monophasic: Fixed dose of hormones throughout month Biphasic: Fixed dose of estrogen, progesterone dose increases during month Triphasic: Varying amounts of hormones during the month Progesterone is present to protect the endometrium from estrogen effects: endometrial cancer Adverse: Thromboembolic disorders and stroke Possible increase of breast cancer Gallbladder disease Migraine Endometriosis Oral Contraceptives and Antibiotics: Rifampin (for TB) induces enzymes in liver that metabolizes the hormones Other antibiotics change intestinal flora and lead to enhanced excretion |
|
Parathyroid hormone
|
Indication: Osteoporosis
MOA: increases calcium and phosphate levels by increasing bone resorption |
|
Calcitonin
|
Indication: Osteoporosis
MOA: Inhibits osteoclast activity and bone resorption |
|
Vitamin D
|
Indication: Osteoporosis
MOA: Facilitates absorption of calcium and phosphate from the small intestine |
|
Calcium
|
Indication: Osteoporosis
Facilitates absorption of calcium and phosphate from the small intestine Some doubt about efficacy |
|
Raloxifene (Evista)
|
Indication: Osteoporosis
Selective Estrogen Receptor Modulator (SERM) Partial agonist: stimulates estrogen receptors in bone, but inhibits in other tissues Effects on bone similar to estrogen: -Decrease resorption of bone -Decrease bone turnover -Increase bone mineral density Adverse: Increased risk of deep vein thrombosis (DVT) Contraindications: Pre-menopausal Pregnancy Concurrent estrogen therapy History of breast cancer |
|
Bisphosphonates
|
Indications:
Osteoporosis - Decrease the incidence of fractures Paget’s Disease -Reduce bone turnover rate -Slow disease progression MOA: Inhibition of farnesyl diphosphate synthase Reduction of geranylgeranyl diphosphate Decrease of GTPase prenylation -Osteoclast inactivation -Osteoclast apoptosis -Inhibition of osteoclast formation Adverse: Osteonecrosis of the Jaw -1st symptom - absent or delayed hard and soft tissue healing after extractions -May remain asymptomatic - exposed bone in oral cavity becomes secondarily infected, trauma to soft tissues from the exposed bone -Risk factors - dental extractions, infectious disease, ill-fitting dentures, bone manipulation, poor oral health, concomitant therapy with steroids, chemo, immunotherapy, 6% of patients on oral therapy Types: Alendronate (Fosamax) Zoledronate (Zometa) Ibandronate (Boniva) once a month Risedronate (Actonel) Pamidronate (Aredia) Etidronate (Didronel) Zoledronic Acid (Reclast) once a year 15 min infusion Tiludronate (Skelid) |
|
Insulin
|
MOA: Insulin binds to tyrosine kinase growth factor receptor
Kinase cascade causes translocation of glucose transporter Glucose transporter fuses with the membrane Increased glucose uptake Effects: Carbohydrates -Increase glucose transport -Increase glycogen synthesis -Increase glycolysis -Inhibits gluconeogenesis Proteins -Increase protein synthesis -Increase amino acid transport Fats -Increase lipoprotein lipase activity -Increase fat storage -Inhibits lipolysis -Increase hepatic lipoprotein synthesis -Inhibits fatty acid oxidation Adverse: Hypoglycemia (sweating, weakness, tremor, confusion, blurred vision, altered behavior) Weight Gain |
|
Lispro (Humalog)
|
MOA: Identical to regular human insulin, except for transposed lysine and proline in B chain
Hexamers and dimers bind 300 times weaker Use: Injected 15 minutes before eating Peak action in minutes rather than 2 hours (advantage over regular) Duration of action is less than one hour instead of several hours as with regular Reduces after meal hyperglycemic episodes and hypoglycemia later |
|
Detemir (Levemir)
|
Use:
Human insulin that binds to albumin (serum protein) via a fatty acid linkage Slow absorption and longer duration of action (up to 24 hours) Indicated for basal therapy in type 1 with a once or twice daily dosing and as add on therapy in type 2 No drug interactions with other protein bound drugs because it is tightly bound |
|
Glargine (Lantus)
|
pH=4
Use: Causes more pain at injection site Acidic solution is neutralized in body Insulin slowly precipitates into crystals Slowly absorbed over 24 hours Given once daily at bedtime |
|
Pramlintide (Symlin)
|
Synthetic analog of amylin
Use: Used only in combination with insulin in type I and type II diabetes Decreases glucose levels in the 3 hours after meals Provides a more “tight” control of glucose levels Given by injection before meals Patients have to be motivated -Test glucose before and after every meal and at bedtime -Participate in diabetes education -Understand how to adjust dose of both insulin and Symlin |
|
Exenatide (Byetta)
|
Class: Incretin Mimetic
Synthetic analog of GLP-1 Effects: Slows gastric emptying- drug interactions Used only in Type 2 Diabetes 1st phase insulin response |
|
Glyburide, Glipizide (DiaBeta, Glucotrol)
|
Class: Sulfonylurea
Mechanism: Stimulate insulin release by blocking ATP dependent K+ current in pancreatic β cells Adverse Effects: Hypoglycemia, Nausea and vomiting, weight gain Interactions: Increase Effect -Azole antifungals -Salicylates, ASA -Sulfonamides -NSAIDS -Tricyclic Antidepressants Decrease Effect -Corticosteroids |
|
Metformin (Glucophage)
|
Class: Biguanide
Pharmacological Effects: Decrease hepatic gluconeogenesis Improve tissue sensitivity to insulin Decrease peripheral glucose uptake Decrease intestinal absorption of glucose |
|
Pioglitazone (Actos)
|
Class: Thiazolidinedione
Mechanism: Post-receptor insulin mimetic activity affecting insulin receptor kinase activity and insulin receptor phosphorylation Pharmacological Effects: Increase insulin sensitivity of tissues Metabolized by p450s, interact with ketoconazole Black box warning: Increase a person's risk of CHF 83,000 major heart problems since 1999 Might be taken off market Increase the body's tendency to accumulate fluids due to inadequate pumping from the heart |
|
Rosiglitazone (Avandia)
|
Class: Thiazolidinedione
Mechanism: Post-receptor insulin mimetic activity affecting insulin receptor kinase activity and insulin receptor phosphorylation Pharmacological Effects: Increase insulin sensitivity of tissues Metabolized by p450s, interact with ketoconazole Black box warning: Increase a person's risk of CHF 83,000 major heart problems since 1999 Might be taken off market Increase the body's tendency to accumulate fluids due to inadequate pumping from the heart |
|
Acarbose (Precose)
|
Class: α glucosidase inhibitor
MOA: Competitive and reversible inhibitor of α glucosidase, hydrolase, pancreatic α amylase Delay in the breakdown of carbohydrates to glucose |
|
Sitagliptin (Januvia)
|
Class: Dipeptidyl peptidase 4 (DPP-4) Inhibitor
MOA: Slows the inactivation of incretin (stimulator of insulin secretion, glucose dependent synthesis of insulin, inactivated by DPP-4hormones) by inhibiting DPP-4 |
|
Glucagon
|
Indications:
-Look for Whipples Triad 1.blood sugar <65 2.symptoms of Catecholamine release 3.improvement of symptoms with glucose administration -Hypoglycemia (<30mg/dL )is immediately life-threatening – “hypoglycemic encephalopathy” Use: Need Emerg Kit: 1 mg Glucagon , Can give IM, works rapidly(within 4 min) to raise blood sugar Watch closely those people who have had frequent lows over the past several weeks |